[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE375795T1 - Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs - Google Patents

Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Info

Publication number
ATE375795T1
ATE375795T1 AT06011784T AT06011784T ATE375795T1 AT E375795 T1 ATE375795 T1 AT E375795T1 AT 06011784 T AT06011784 T AT 06011784T AT 06011784 T AT06011784 T AT 06011784T AT E375795 T1 ATE375795 T1 AT E375795T1
Authority
AT
Austria
Prior art keywords
dexamethasone
cancer
treatment
combination therapy
therapy
Prior art date
Application number
AT06011784T
Other languages
English (en)
Inventor
Esteban Cvitkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean-Louis Misset
Chris Twelves
Hoff Daniel D Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE375795T1 publication Critical patent/ATE375795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT06011784T 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs ATE375795T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
ATE375795T1 true ATE375795T1 (de) 2007-11-15

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Country Status (32)

Country Link
US (1) US8119638B2 (de)
EP (3) EP1702618B1 (de)
JP (2) JP2002544231A (de)
KR (1) KR20020019914A (de)
CN (2) CN1360503A (de)
AR (1) AR028476A1 (de)
AT (3) ATE375795T1 (de)
AU (2) AU777417B2 (de)
BG (1) BG65680B1 (de)
BR (1) BR0010531A (de)
CA (1) CA2373794C (de)
CY (4) CY1105818T1 (de)
CZ (1) CZ301482B6 (de)
DE (4) DE60030554T8 (de)
DK (3) DK1716853T3 (de)
ES (2) ES2294756T3 (de)
FR (1) FR08C0013I2 (de)
HU (2) HU229866B1 (de)
IL (2) IL146434A0 (de)
LU (1) LU91418I2 (de)
MX (1) MXPA01011562A (de)
MY (1) MY164077A (de)
NL (1) NL300337I2 (de)
NO (2) NO324564B1 (de)
NZ (1) NZ515423A (de)
PL (1) PL198185B1 (de)
PT (3) PT1176964E (de)
SI (3) SI1716853T1 (de)
SK (1) SK287580B6 (de)
TR (1) TR200103819T2 (de)
UA (1) UA74782C2 (de)
WO (1) WO2000069441A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PL1689404T3 (pl) * 2003-11-13 2009-02-27 Pharma Mar Sau Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
EP1691809A1 (de) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
UA87877C2 (en) * 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100009906A1 (en) * 2006-05-12 2010-01-14 Pharma Mar, S.A. Anticancer Treatments
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
BR112018015118A2 (pt) * 2016-02-04 2018-12-18 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica injetável inclusiva de trabectedina para uso externo gastrointestinal e método de fabricação da mesma
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
AU2021256746A1 (en) 2020-04-15 2022-11-03 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
ATE69234T1 (de) * 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
EP2298300A1 (de) * 1996-11-05 2011-03-23 The Children's Medical Center Corporation Zusammensetzungen zur Inhibition der Angiogenese enhaltend Thalidomide und Aspirin
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
KR100603219B1 (ko) 1998-04-06 2006-07-20 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 반합성 엑테이나시딘
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (de) 2000-08-11 2003-10-29 City of Hope Der antineoplastische wirkstoff et-743 inhibiert die transaktivierung durch sxr
CN100374162C (zh) 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
EP1360337A1 (de) 2001-02-09 2003-11-12 The Regents Of The University Of California Mitglieder der ecteinascidin familie: zusammensetzungen und methoden
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CA2462502A1 (en) 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PL1689404T3 (pl) 2003-11-13 2009-02-27 Pharma Mar Sau Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (de) 2003-11-14 2006-08-23 Pharma Mar, S.A. Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
US20080293725A1 (en) 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
CA2583464A1 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
UA87877C2 (en) 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20100009906A1 (en) 2006-05-12 2010-01-14 Pharma Mar, S.A. Anticancer Treatments

Also Published As

Publication number Publication date
SI1176964T1 (sl) 2007-02-28
DE60030554D1 (de) 2006-10-19
AU777417B2 (en) 2004-10-14
HUS1500001I1 (hu) 2016-08-29
CY2008007I1 (el) 2009-11-04
BG65680B1 (bg) 2009-06-30
CY1112753T1 (el) 2016-02-10
HUP0201187A3 (en) 2002-11-28
EP1716853A2 (de) 2006-11-02
EP1716853B9 (de) 2011-09-28
JP5777562B2 (ja) 2015-09-09
ATE500830T1 (de) 2011-03-15
EP1716853A3 (de) 2006-11-15
NO324564B1 (no) 2007-11-19
CN1679631A (zh) 2005-10-12
WO2000069441A1 (en) 2000-11-23
CY2008007I2 (el) 2009-11-04
NO20015516D0 (no) 2001-11-12
NL300337I1 (nl) 2008-05-01
EP1716853B1 (de) 2011-03-09
DK1176964T3 (da) 2007-01-15
NO20015516L (no) 2002-01-11
DK1702618T3 (da) 2008-02-25
NO2008005I2 (de) 2010-09-27
EP1176964A1 (de) 2002-02-06
ES2272279T3 (es) 2007-05-01
CY1105818T1 (el) 2011-02-02
US8119638B2 (en) 2012-02-21
DE60030554T2 (de) 2007-09-13
EP1176964B8 (de) 2007-10-10
UA74782C2 (uk) 2006-02-15
PT1716853E (pt) 2011-05-12
CA2373794A1 (en) 2000-11-23
JP2002544231A (ja) 2002-12-24
EP1702618A2 (de) 2006-09-20
CZ20014081A3 (cs) 2002-11-13
LU91418I9 (de) 2019-01-02
LU91418I2 (fr) 2008-05-13
CA2373794C (en) 2005-10-11
SK16442001A3 (sk) 2002-03-05
SK287580B6 (sk) 2011-03-04
NO2008005I1 (no) 2008-06-09
NZ515423A (en) 2004-04-30
PL198185B1 (pl) 2008-06-30
CN1360503A (zh) 2002-07-24
BG106171A (en) 2002-06-28
CY1107143T1 (el) 2010-07-28
PL352931A1 (en) 2003-09-22
AU2005200180A1 (en) 2005-02-10
ATE338552T1 (de) 2006-09-15
AR028476A1 (es) 2003-05-14
TR200103819T2 (tr) 2002-04-22
MXPA01011562A (es) 2002-07-30
DE60030554T8 (de) 2008-01-10
DE60036826D1 (de) 2007-11-29
HU229866B1 (en) 2014-10-28
EP1702618A3 (de) 2006-12-27
DE122008000013I1 (de) 2008-08-07
IL146434A0 (en) 2002-07-25
US20070275942A1 (en) 2007-11-29
CZ301482B6 (cs) 2010-03-17
JP2012149095A (ja) 2012-08-09
DK1716853T3 (da) 2011-06-27
SI1702618T1 (sl) 2008-02-29
NL300337I2 (nl) 2008-09-01
SI1716853T1 (sl) 2011-10-28
EP1702618B1 (de) 2007-10-17
KR20020019914A (ko) 2002-03-13
PT1702618E (pt) 2008-01-11
CN100477993C (zh) 2009-04-15
EP1176964B1 (de) 2006-09-06
FR08C0013I1 (de) 2008-05-30
AU2005200180B9 (en) 2008-05-29
FR08C0013I2 (fr) 2009-10-30
PT1176964E (pt) 2007-01-31
AU4597500A (en) 2000-12-05
BR0010531A (pt) 2002-06-04
HUP0201187A2 (en) 2002-09-28
AU2005200180B2 (en) 2007-12-13
DE60045720D1 (de) 2011-04-21
DE60036826T2 (de) 2008-08-28
MY164077A (en) 2017-11-30
IL146434A (en) 2008-03-20
ES2294756T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
DE60036826D1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60032226D1 (de) Verfahren zur induktion von krebszellentod und tumorregression
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
NO20012160D0 (no) Anordning for behandling av makulös degenerering
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DE60112423D1 (de) Verwendung von substituierten distamycin-acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
ATE353664T1 (de) Hcg therapie zur behandlung von metastatischem brustkrebs